Seeking Alpha

Merck (MRK) will continue recording sales and profits from acid reflux drugs Nexium and Prilosec...

Merck (MRK) will continue recording sales and profits from acid reflux drugs Nexium and Prilosec for at least another two years after AstraZenica (AZN) agreed not to exercise an option this year to acquire Merck's remaining interest in a partnership connected to the treatments. Merck expects the deal to add $200M to revenue and $0.03-$0.05 in EPS in 2012. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|